TNSN06050A1 - Anticorps modifies contre le igf-1r humain - Google Patents

Anticorps modifies contre le igf-1r humain

Info

Publication number
TNSN06050A1
TNSN06050A1 TNP2006000050A TNSN06050A TNSN06050A1 TN SN06050 A1 TNSN06050 A1 TN SN06050A1 TN P2006000050 A TNP2006000050 A TN P2006000050A TN SN06050 A TNSN06050 A TN SN06050A TN SN06050 A1 TNSN06050 A1 TN SN06050A1
Authority
TN
Tunisia
Prior art keywords
igf
résidus
antibodies against
against human
modified antibodies
Prior art date
Application number
TNP2006000050A
Other languages
English (en)
Inventor
Vahe Bedian
Bruce David Cohen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN06050A1 publication Critical patent/TNSN06050A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des anticorps humains, par exemple ceux dirigés contre le récepteur de IGF-1 humain (IGF-1R) qui sont destinés au traitement du cancer, qui possèdent un ou plusieurs résidus mutés choisis remplacés par des résidus de lignée germinale. Un résidu replacé peut être une mutation somatique dans une région de squelette structural.
TNP2006000050A 2003-08-13 2006-02-13 Anticorps modifies contre le igf-1r humain TNSN06050A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49520003P 2003-08-13 2003-08-13
PCT/IB2004/002555 WO2005016967A2 (fr) 2003-08-13 2004-08-03 Anticorps modifies diriges contre le igf-1r humain

Publications (1)

Publication Number Publication Date
TNSN06050A1 true TNSN06050A1 (fr) 2007-10-03

Family

ID=34193291

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000050A TNSN06050A1 (fr) 2003-08-13 2006-02-13 Anticorps modifies contre le igf-1r humain

Country Status (37)

Country Link
US (2) US7371378B2 (fr)
EP (1) EP1656391B1 (fr)
JP (1) JP4638870B2 (fr)
KR (1) KR100825156B1 (fr)
CN (1) CN1835975B (fr)
AP (1) AP2006003510A0 (fr)
AR (1) AR045247A1 (fr)
AT (1) ATE484525T1 (fr)
AU (1) AU2004265152A1 (fr)
BR (1) BRPI0413466A (fr)
CA (1) CA2535071A1 (fr)
CL (1) CL2004002035A1 (fr)
CR (1) CR8233A (fr)
DE (1) DE602004029581D1 (fr)
DK (1) DK1656391T3 (fr)
EA (1) EA200600234A1 (fr)
EC (1) ECSP066359A (fr)
ES (1) ES2351395T3 (fr)
GT (1) GT200400158A (fr)
IL (1) IL173273A (fr)
IS (1) IS8266A (fr)
MA (1) MA27988A1 (fr)
MX (1) MXPA06001634A (fr)
NL (1) NL1026829C2 (fr)
NO (1) NO20060542L (fr)
OA (1) OA13234A (fr)
PA (1) PA8608801A1 (fr)
PE (1) PE20050339A1 (fr)
PL (1) PL1656391T3 (fr)
PT (1) PT1656391E (fr)
RS (1) RS20060099A (fr)
TN (1) TNSN06050A1 (fr)
TW (1) TWI294915B (fr)
UA (1) UA85058C2 (fr)
UY (1) UY28464A1 (fr)
WO (1) WO2005016967A2 (fr)
ZA (1) ZA200601231B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL228041B1 (pl) 2001-01-05 2018-02-28 Amgen Fremont Inc Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierajaca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana czasteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierze transgeniczne.
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7638605B2 (en) * 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
EP1694850B1 (fr) 2003-11-12 2011-06-29 Schering Corporation Systeme de plasmide pour l'expression multigenique
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP1802341A1 (fr) 2004-07-16 2007-07-04 Pfizer Products Inc. Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) * 2005-01-10 2005-02-16 Cambridge Antibody Tech Method of mutagenesis
CA2604393A1 (fr) * 2005-04-15 2006-10-26 Schering Corporation Methodes et compositions pour le traitement ou la prevention du cancer
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
ES2452115T3 (es) 2005-06-17 2014-03-31 Imclone Llc Un anticuerpo anti-PDGFRalfa para su uso en el tratamiento de cáncer de huesos metastásico
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JP5198289B2 (ja) * 2006-02-03 2013-05-15 イムクローン・リミテッド・ライアビリティ・カンパニー 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト
EP1998806A1 (fr) * 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Formulation d'anticorps monoclonal humain anti-igf-1r
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CA2653745C (fr) * 2006-06-02 2013-11-19 Pfizer Products Inc. Analyse de cellules tumorales circulantes
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
US20100166747A1 (en) * 2007-03-02 2010-07-01 Beltran Pedro J Methods and compositions for treating tumor diseases
AU2008228823A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
WO2008144345A2 (fr) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarqueurs et procédés pour déterminer la sensibilité de modulateurs de récepteur de facteur de croissance de type 1 semblable à l'insuline
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
EP2259797A2 (fr) * 2008-03-25 2010-12-15 Schering Corporation Procédés de traitement ou de prévention de cancer colorectal
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
EP2356154A4 (fr) * 2008-11-06 2012-12-19 Alexion Pharma Inc Mise au point d anticorps à immunogénicité réduite et méthodes de fabrication associées
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
WO2010146059A2 (fr) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarqueurs pour une thérapie par inhibiteur d'igf-1r
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
EP2494070A2 (fr) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
WO2011075861A1 (fr) * 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Procédé pour faire baisser l'immunogénicité
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011161119A1 (fr) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Anticorps contre le récepteur du facteur de croissance insulinique i et ses utilisations
WO2012007896A1 (fr) 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Conjugués d'anticorps multifonctionnels
WO2012106556A2 (fr) 2011-02-02 2012-08-09 Amgen Inc. Méthodes et compositions associées à l'inhibition d'igf-1r
EP3536708A1 (fr) 2011-04-19 2019-09-11 Pfizer Inc Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP2802355B1 (fr) * 2012-01-09 2018-09-05 CovX Technologies Ireland Limited Anticorps mutants et leur conjugaison
EP2631653A1 (fr) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification de modulateurs de liaison des propriétés d'anticorps réactifs avec un élément de la famille des récepteurs de l'insuline
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
EP2917236A2 (fr) * 2012-11-06 2015-09-16 MedImmune, LLC Polythérapies à l'aide de molécules de liaison anti-pseudomonas psl et pcrv
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CN103319598B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 抗胰岛素样生长因子-1受体抗体及其编码基因和应用
CN110981957A (zh) 2014-01-15 2020-04-10 豪夫迈·罗氏有限公司 具有改善的蛋白A结合作用的Fc区变体
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
US20200407445A1 (en) * 2017-07-27 2020-12-31 Iteos Therapeutics Sa Anti-tigit antibodies
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0821671B1 (fr) 1995-04-20 2000-12-27 Pfizer Inc. Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
TR199900066T2 (xx) 1996-07-18 1999-04-21 Pfizer Inc. Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
WO1999060023A1 (fr) 1998-05-15 1999-11-25 Imclone Systems Incorporated Traitement de tumeurs humaines a l'aide d'un rayonnement et d'inhibiteurs de tyrosine kinases de recepteurs du facteur de croissance
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
TR200501367T2 (tr) 1999-03-25 2005-09-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
ES1042735Y (es) 1999-04-07 2000-02-16 Martinez Fernando Martinez Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de) 2000-07-12 2003-07-31 Karlsruhe Forschzent HTS-Kryomagnet und Aufmagnetisierungsverfahren
PL228041B1 (pl) 2001-01-05 2018-02-28 Amgen Fremont Inc Przeciwciało przeciwko receptorowi insulinopodobnego czynnika wzrostu I, zawierajaca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana czasteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierze transgeniczne.
KR20030074839A (ko) 2001-02-19 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체
ES2427964T3 (es) 2002-01-18 2013-11-05 Pierre Fabre Medicament Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
JP4335130B2 (ja) 2002-04-30 2009-09-30 協和発酵キリン株式会社 ヒトインスリン様成長因子に対する抗体
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
NZ582210A (en) 2003-02-13 2011-04-29 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
CA2519113C (fr) 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Anticorps contre le recepteur du facteur de croissance 1 analogue a l'insuline et utilisations de ceux-ci
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.

Also Published As

Publication number Publication date
NL1026829A1 (nl) 2005-02-15
MXPA06001634A (es) 2006-04-28
DE602004029581D1 (de) 2010-11-25
AU2004265152A1 (en) 2005-02-24
CN1835975A (zh) 2006-09-20
EP1656391B1 (fr) 2010-10-13
PA8608801A1 (es) 2005-03-03
IS8266A (is) 2006-01-26
TW200516145A (en) 2005-05-16
US7575746B2 (en) 2009-08-18
UA85058C2 (ru) 2008-12-25
ECSP066359A (es) 2006-10-31
CR8233A (es) 2007-01-18
AP2006003510A0 (en) 2006-02-28
PE20050339A1 (es) 2005-05-17
JP2007527705A (ja) 2007-10-04
EA200600234A1 (ru) 2006-08-25
AR045247A1 (es) 2005-10-19
ATE484525T1 (de) 2010-10-15
BRPI0413466A (pt) 2006-10-17
UY28464A1 (es) 2005-03-31
RS20060099A (en) 2008-08-07
KR100825156B1 (ko) 2008-04-24
JP4638870B2 (ja) 2011-02-23
IL173273A (en) 2011-10-31
DK1656391T3 (da) 2011-01-03
EP1656391A2 (fr) 2006-05-17
WO2005016967A2 (fr) 2005-02-24
NL1026829C2 (nl) 2005-07-05
OA13234A (en) 2006-12-13
PL1656391T3 (pl) 2011-03-31
CN1835975B (zh) 2012-11-21
KR20060035796A (ko) 2006-04-26
NO20060542L (no) 2006-05-03
CA2535071A1 (fr) 2005-02-24
WO2005016967A3 (fr) 2005-04-14
US20050069539A1 (en) 2005-03-31
ES2351395T3 (es) 2011-02-04
IL173273A0 (en) 2006-06-11
US20080181891A1 (en) 2008-07-31
CL2004002035A1 (es) 2005-06-03
TWI294915B (en) 2008-03-21
US7371378B2 (en) 2008-05-13
GT200400158A (es) 2005-07-22
ZA200601231B (en) 2007-05-30
MA27988A1 (fr) 2006-07-03
PT1656391E (pt) 2010-12-06

Similar Documents

Publication Publication Date Title
TNSN06050A1 (fr) Anticorps modifies contre le igf-1r humain
TNSN06210A1 (fr) Nitro-oxydérivés de prostaglandines
ATE469211T1 (de) Verbesserte sso7-polymerase-konjugat-proteine
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
MY163480A (en) Sclerostin binding agents
CY1116913T1 (el) Τροποποιημενα κλασματα fab αντισωματων
TW200639182A (en) Antibody variants and uses thereof
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
RS80704A (en) ANTI- av?6.ANTIBODIES
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
EA200870130A1 (ru) Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
UA92505C2 (ru) Композиции на основе антитела против cd3
MX337423B (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
NO20062672L (no) Interleukin-10-antistoffer
CR8231A (es) Anticuerpos rg1 y uso de los mismos
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
MY174493A (en) Binding agents
CO5720212A1 (es) Composicion de anticuerpo her2
EE200300408A (et) Aktiivsete valkude saagise suurendamine
UY3402Q (es) Diseno de tractor
MA33387B1 (fr) Polypeptides et procede de traitement
EA200702193A1 (ru) Гликозилирование белков
WO2005048822A3 (fr) Anticorps et/ou conjugues associes se liant au fragment de terminaison amino de l'urokinase, leurs compositions et utilisations
NO20080409L (no) Fremgangsmater og preparater til malsoking av IFNAR2